Late initiation of combination antiretroviral therapy in Canada: a call for a national public health strategy to improve engagement in HIV care

Abstract

Introduction

Combination antiretroviral therapy (ART) significantly decreases morbidity, mortality and HIV transmission. We aimed to characterize the timing of ART initiation based on CD4 cell count from 2000 to 2012 and identify factors associated with late initiation of treatment.

Methods

Participants from the Canadian Observational Cohort (CANOC), a multi-site cohort of HIV-positive adults initiating ART naively after 1 January 2000, in three Canadian provinces (British Columbia, Ontario and Québec) were included. Late initiation was defined as a CD4 count <200 cells/mm³ or an AIDS-defining illness before ART initiation (baseline). Temporal trends were assessed using the Cochran–Armitage test, and independent correlates of late initiation were identified using logistic regression.

Results

In total, 8942 participants (18% female) of median age 40 years (Q1–Q3 33–47) were included. The median baseline CD4 count increased from 190 cells/mm³ (Q1–Q3 80–320) in 2000 to 360 cells/mm³ (Q1–Q3 220–490) in 2012 (p<0.001). Overall, 4274 participants (48%) initiated ART with a CD4 count <200 cells/mm³ or AIDS-defining illness. Late initiation was more common among women, non-MSM, older individuals, participants from Ontario and BC (vs. Québec), persons with injection drug use (IDU) history and individuals starting ART in earlier calendar years. In sub-analysis exploring recent (2008 to 2012) predictors using an updated CD4 criterion (<350 cells/mm³), IDU and residence in BC (vs. Québec) were no longer significant correlates of late initiation.

Conclusions

This analysis documents increasing baseline CD4 counts over time among Canadians initiating ART. However, CD4 counts at ART initiation remain below contemporary treatment guidelines, highlighting the need for strategies to improve earlier engagement in HIV care.

References Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA. 2001;286(20):2568–77. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360(18):1815–26. May M, Gompels M, Delpech V, Porter K, Post F, Johnson M, et al. Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ. 2011;343:d6016. Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis. 2008;197(8):1133–44. Althoff KN, Gange SJ, Klein MB, Brooks JT, Hogg RS, Bosch RJ, et al. Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis. 2010;50(11):1512–20. Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373(9672):1352. Gay CL, Napravnik S, Eron JJ Jr. Advanced immunosuppression at entry to HIV care in the southeastern United States and associated risk factors. AIDS. 2006;20(5):775–8. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994;331(18):1173–80. Garcia PM, Kalish LA, Pitt J, Minkoff H, Quinn TC, Burchett SK, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. N Engl J Med. 1999;341(6):394–402. Volmink J, Siegfried N, van der Merwe L, Brocklehurst P. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev. 2007;(1):CD003510. Montaner JS, Hogg R, Wood E, Kerr T, Tyndall M, Levy AR, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet. 2006;368(9534):531–6. Attia S, Egger M, Muller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS. 2009;23(11):1397–404. Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, Cohen CR, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375(9731):2092–8. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505. Montaner JS, Lima VD, Barrios R, Yip B, Wood E, Kerr T, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet. 2010;376(9740):532–9. Fang CT, Hsu HM, Twu SJ, Chen MY, Chang YY, Hwang JS, et al. Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J Infect Dis. 2004;190(5):879–85. Wood E, Kerr T, Marshall BD, Li K, Zhang R, Hogg RS, et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ. 2009;338. Das M, Chu PL, Santos GM, Scheer S, Vittinghoff E, McFarland W, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One. 2010;5(6):e11068. Gardner EM, McLees MP, Steiner JF, del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52(6):793–800. Palmer AK, Klein MB, Raboud J, Cooper C, Hosein S, Loutfy M, et al. Cohort profile: the Canadian Observational Cohort collaboration. Int J Epidemiol. 2011;40(1):25–32. Hogg RS, Heath K, Lima VD, Nosyk B, Kanters S, Wood E, et al. Disparities in the burden of HIV/AIDS in Canada. PLoS One. 2012;7(11):e47260. Hammer SM, Eron JJ, Reiss P, Schooley RT, Thompson MA, Walmsley S, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society–USA panel. JAMA. 2008;300(5):555–70. Thompson MA, Aberg JA, Cahn P, Montaner JSG, Rizzardini G, Telenti A, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society–USA panel. JAMA. 2010;304(3):321–33. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society–USA panel. JAMA. 2012;308(4):387–402. Department of Health and Human Services. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2013 [cited 2015 Jul 30]. Available from: http://aidsinfo.nih.gov/contentfiles/adultandadolescentgl.pdf Lane HC, Neaton JD. When to start therapy for HIV infection: a swinging pendulum in search of data. Ann Intern Med. 2003;138(8):680–1. Burman WJ, Reves RR, Cohn DL. The case for conservative management of early HIV disease. JAMA. 1998;280(1):93–5. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. 2013 [cited 2015 Jul 30]. Available from: http://www.who.int/hiv/pub/guidelines/arv2013/en/ INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807. British Columbia Centre for Excellence in HIV/AIDS Therapeutic Guidelines Committee. Therapeutic guidelines: antiretroviral (ARV) treatment of adult HIV infection. 2013 [cited 2015 Jul 30]. Available from: http://www.cfenet.ubc.ca/therapeutic-guidelines Gouvernement du Quebec. La therapie antiretrovirale pour les adultes infectes par le VIH: Guide pour les professionnels de la sante du Quebec. 2015 [cited 2015 Jul 30]. Available from: http://publications.msss.gouv.qc.ca/acrobat/f/documentation/2014/14-337-01W.pdf Aziz M, Smith KY. Treating women with HIV: is it different than treating men? Curr HIV/AIDS Rep. 2012;9(2):171–8. Nicastri E, Leone S, Angeletti C, Palmisano L, Sarmati L, Chiesi A, et al. Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review. J Antimicrob Chemother. 2007;60(4):724–32. Sabin CA, Smith CJ, Gumley H, Murphy G, Lampe FC, Phillips AN, et al. Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy. AIDS. 2004;18(16):2145–51. Mocroft A, Lundgren JD, Sabin ML, Monforte A, Brockmeyer N, Casabona J, et al. Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med. 2013;10(9):1001510. Shivaji T, Diniz A, Cortes-Martins H. Characteristics of late presentation of HIV infection in MSM and heterosexual adults in Portugal 2011–2013. J Int AIDS Soc. 2014;17(4 Suppl 3):19690. Raboud J, Blitz S, Walmsley S, Thompson C, Rourke SB, Loutfy MR, et al. Effect of gender and calendar year on time to and duration of virologic suppression among antiretroviral-naive HIV-infected individuals initiating combination antiretroviral therapy. HIV Clin Trials. 2010;11(6):340–50. Cescon A, Patterson S, Chan K, Palmer AK, Margolese S, Burchell AN, et al. Gender differences in clinical outcomes among HIV-positive individuals on antiretroviral therapy in Canada: a multisite cohort study. PLoS One. 2013; 8(12):e83649. Palmer AK, Cescon A, Chan K, Cooper C, Raboud JM, Miller CL, et al. Factors associated with late initiation of highly active antiretroviral therapy among young HIV-positive men and women aged 18 to 29 years in Canada. J Int Assoc Provid AIDS Care. 2014;13(1):56–62. Carter A, Min JE, Chau W, Lima VD, Kestler M, Pick N, et al. Gender inequities in quality of care among HIV-positive individuals initiating antiretroviral treatment in British Columbia, Canada (2000–2010). PLoS One. 2014; 9(3):92334. Public Health Agency of Canada. Summary: estimates of HIV prevalence and incidence in Canada, 2011. 2012 [cited 2015 Jul 30]. Available from: http://www.phac-aspc.gc.ca/aids-sida/publication/survreport/estimat2011-eng.php Wood E, Kerr T, Tyndall MW, Montaner JS. A review of barriers and facilitators of HIV treatment among injection drug users. AIDS. 2008;22(11):1247–56. Uhlmann S, Milloy MJ, Kerr T, Zhang R, Guillemi S, Marsh D, et al. Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users. Addiction. 2010;105(5):907–13. Lourenco L, Samji H, Nohpal A, Chau W, Colley G, Lepik K, et al. Declines in highly active antiretroviral therapy initiation at CD4 cell counts ≤ 200 cells/µL and the contribution of diagnosis of HIV at CD4 cell counts ≤ 200 cells/µL in British Columbia, Canada. HIV Med. 2015;16(6):337–45. Krentz H, Auld M, Gill M. The high cost of medical care for patients who present late (CD4 < 200 cells/uL) with HIV infection. HIV Med. 2004;5(2):93–8. Plitt SS, Mihalicz D, Singh AE, Jayaraman G, Houston S, Lee BE. Time to testing and accessing care among a population of newly diagnosed patients with HIV with a high proportion of Canadian Aboriginals, 1998–2003. AIDS Patient Care STDS. 2009;23(2):93–9. Jaworsky D, Monette L, Raboud J, O'Brien-Teengs D, Diong C, Blitz S, et al. Comparison of late HIV diagnosis as a marker of care for Aboriginal versus non-Aboriginal people living with HIV in Ontario. Can J Infect Dis Med Microbiol. 2012;23(4):96. Gustafson R, Montaner J, Sibbald B. Seek and treat to optimize HIV and AIDS prevention. CMAJ. 2012;184(18):1971. Public Health Agency of Canada. HIV screening and testing guide. 2013 [cited 2015 Jul 30]. Available from: http://www.phac-aspc.gc.ca/aids-sida/guide/hivstg-vihgdd-eng.php Office of the Provincial Health Officer. HIV testing guidelines for the province of British Columbia. 2014 [cited 2015 Jul 30]. Available from: http://hivguide.ca UNAIDS. 90-90-90: an ambitious treatment target to help end the AIDS epidemic. 2014 [cited 2015 Jul 30]. Available from: http://www.unaids.org/en/resources/documents/2014/90-90-90